Amid safety concerns, FDA grants two new JAK approvals — but with added warnings and a key label change
After a post-marketing trial for Pfizer’s Xeljanz turned up concerning safety results at the beginning of the year, thwarting the whole JAK class, the FDA is finally rolling out some new approvals — but with added warnings and a key label change.
Both Xeljanz and AbbVie’s Rinvoq got cleared for new indications on Tuesday, but on one condition: They can only be taken after a patient has failed on one or more tumor necrosis factor (TNF) blockers, like Humira or Enbrel.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.